1st, 2nd, 3Rd OctObeR 2012Cité Internationale Universitaire of Paris, France

3rd editiOn

InnovatIon Days 2012 HIgHlIgHts Unique international partnering event in Paris

Innovation showcase

Early-stage licensing opportunities

Cité Internationale Universitaire27 Boulevard Jourdan • 75014 Paris

Pre l iminar y Program

I N N O V A T I O N D A Y S P R E S E N T A T I O N

About the conference

An overview of Innovation Days 2011

the Innovation Days continue the

tradition of providing early-stage

lifescience companies with high

caliber partnering opportunities. the

event enables delegates to power their

network from innovative start-ups to

pharma and investors. the Innovation

Days are the unique place dedicated

to the identification, assessment,

presentation of the most innovative

projects through Europe.

More than 500 scheduled one-to-one meetings

over 550 attendees

260 companies

16 biotech presentations

40 exhibitors

18 countries represented

40 speakers, leading conferences, round tables and workshops

I N N O V A T I O N D A Y S P R E S E N T A T I O N

Innovation Days Highlights

Excellent early-stage networking opportunities

selected Biotechnology companies presentations

Interactive workshops and panels feature industry experts

state-of-the-art partnering software

International exhibition of major new products and solutions

Who will you meet?

ORiGinALitY innOVAtiOnstRAteGY

Researchers

Biotech

Pharma

Other (CRO, Service Providers, Government, Agencies, Associations, Universities, Press...)

Emerging biotech companies

academic researchers and Innovation Prize candidates

Pharmaceutical companies

Institutional representatives

Clusters and bioparks

P R E l I m I N A R Y P R O G R A m m O N D A Y , O C T O B E R 1 S T , 2 0 1 2

10:15 - 11:00 Plenary session

9:30 - 10:15 Keynote opening address

9:20 - 9:30 Welcome and opening remarks

9:00 Registration and Exhibition open Continental Breakfast

11:00 - 11:30 networking break

the Place of Open innovation in the biotechnology and Healthcare sector in 2012: Facts and challenges

the industry is clearly grappling with a significant need to change its innovation model and engage in new way of thinking. If internal R&D and external alliances remain the leading source of innovation, there is an emerging trend towards open Innovation. the concept is being seen as an effective way to stimulate new ideas and to innovate more cost effectively.

Can open Innovation really solve pharma’s productivity crisis?this high-level presentation will deliver views from various stakeholders in the innovation process in order to debate the reality of the open Innovation Concept:

the open Innovation agenda and evidence: Has it really worked so far for Pharma? Is it making any difference in the market? overcoming the challenges inherent in open Innovation: Process coordination, Management of Intellectual Property, Research Costs

How Pharma are applying open Innovation in their business model?

Rafi MARdAcHti, President & CEo, Universal Medica Group

claude beRtRAnd, vice-Président Executif R&D, Chief scientific officer, ipsen Group, (FR) Pascale AUGe, Entrepreneurship & technology transfer service, institut Pasteur, (FR) Ludo LAUWeRs, vice Chairman of the Board, Janssen Pharmaceutica, svP, J&J (B)

Manfred HORst, Director licensing & External Research Europe, Merck&co (D) Patrick FAURe, Executive Director, Health and life sciences Department, sAtt-ValorPaca (FR) Garold bReit, Executive Director, University of Manitoba (Usa) Michel GOLdMAn, Executive Director, iMi (B)

Fostering early-stage Partnership Among Pharma and Academia

Driven in part by the dearth of vC available for early-stage start-ups and competition for late-stage in-licensing candidates, pharma companies are turning to academic institutions to foster early stage partnerships. these collaborations can be a way to access technologies and engage with talent already at university level. Within the academic institutions, the more commercially minded see these partnerships as a way to move their programs and technologies from the bench into the clinic more efficiently.

How do Pharma and academia overcome conflicting core values, rights to IP, and co-mingling of funds to successfully manage the alliance?

Is there a new drug development business model evolving that reduces the need for venture capital?

this panel will explore the growing importance of academia to the future of Pharma’s R&D pipelines.

P R E l I m I N A R Y P R O G R A m m O N D A Y , O C T O B E R 1 S T , 2 0 1 2

1:00 - 2:00 Lunch

3:30 - 4:00 networking break

2:00 - 3:30 tHeRAPeUtic insiGHt

4:00 - 5:00 Keynote session

bioclusters organizations: sparring partners for innovation

globalization of research and Innovation and global competition are putting a new emphasis on the role of regional clusters and further development.this session will address the way that clusters foster Innovation in life sciences sector thanks to:

Close collaborations between academia and industry access to national investors talented individuals governmental support

through testimonials, the clusters representatives will highlight the key success ingredients that bring fruitful ecosystem to their members and particularly to young innovative companies.

Pr. bruno LinA, Head, national Reference centre for influenza (FR) Dr. John A. tHOMsOn, vP, strategic R&D networks, Vertex Pharmaceuticals incorporated (Usa)

Luc AUJAMe, Director of External Research and Development, sanofi Pasteur (FR)

tony JOnes, Director of Business Development, One nucleus (UK)

Franck MOLinA, Co-founder, eUROMediAG (FR) Peter PAUWeLs, Executive Director, Cancéropôle lyon auvergne Rhône-alpes (cLARA)

11:30 - 1:00 tHeRAPeUtic insiGHt

Pr. Faiez ZAnnAd, Cardiologist and Prof. of therapeutics, inserm and University of Lorraine (FR) Jean-Louis dAsseUx, CEo, cerenis therapeutics (FR) dave Adams, vice President Integrations & Divestitures, Medtronic (Usa)

FOcUs On cARdiOVAscULAR

Cardiovascular disease's effects on world health and the economics of healthcare are devastating. this session will connect the "big picture" with the real world of drug development and commercialization issues. the panel will provide an analysis of standards of care and epidemiology, market dynamics, and will take a close look at trends in cardiovascular partnering deal.

FOcUs On inFectiOUs diseAses

this session will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. these topics will include reviews of emerging treatment of anti-infectives and vaccines in addition to subjects including portfolio value management, license revenue and patent extension strategies.

THERAPEuTIC INSIGHT:"therapeutic Insight" is a new forum of Innovation Days dedicated to industry executives to gain an enriched understanding of transformational challenges emerging across the industry and within the scientific, clinical and commercial spectra of selected diseases and technological areas. therapeutic insight sessions will provide an overview of development and regulatory issues, as well as market dynamics and business development challenges.those forums will be followed by selected Biotech Companies' Presenting session.

P R E l I m I N A R Y P R O G R A m m O N D A Y , O C T O B E R 1 S T , 2 0 1 2

6:00 exhibit Hall Hospitality Reception

5:00 - 6:00 Keynote session

Addressing biotech funding difficultiesWhat makes a biotech company successful?

For young biotechs, attracting seed and early-stage funding has become increasingly difficult in recent years although anecdotal signs of recovery are beginning to emerge.

However it is still possible to identify certain characteristics that make some biotech business models more likely to succeed than others.

this panel will address the strategies being employed by biotech CEos and early-stage investors to ensure an adequately funded R&D pipeline.

trying to figure out the best biotech business model? this session is a great place for biotechnology companies to meet and share ideas.

emma bALAYRe, Innovation Department, ALMA consulting Group (FR) Franck Zal, CEo Hemarina, vP France biotech (FR) Paul-Louis santy, senior Partner, Merieux développement (FR) Pierre-noel LiRsAc, Director of Public Financing of the Cell therapy Programs, LFb Group (FR)

P R E l I m I N A R Y P R O G R A m T u E S D A Y , O C T O B E R 2 N D , 2 0 1 2

9:30 - 10:15 Keynote session

10:15 - 11:00 closing Panel discussion

Human and social science perspectives on biotechnologiesOrganizational solutions and drivers for innovation

Human resources management is an essential criteria for success in a rapidly changing world of scientific understanding and marketplace evolution. However, the biotech industry generally does not feel that the capital produced by its employees is the most precious resource. the social organization, the enterprise culture and its values are key factors of success to translate science and innovation into medicines that make a difference.

this presentation will explore successful initiatives focused on the establishment of a highly functional culture and organization.

setting-up your organization to ensure an environment of innovation, sharing transversally across the organization and establishing a toolkit of practices that work.

Market Access and innovationReverse drug development process to meet changing payer requirements?

In order to launch a successful product, reimbursement needs to be taken into account far earlier in the development lifecycle than in the past.this session will focus on the R&D’s role in developing products with a greater probability of market access:

Developing a disease area strategy for an unmet clinical or economic need, Understanding the willingness of the public or private payer to cover a drug (cost/ differentiation), Insights for early feedback on the feasibility of market access for a developing product.

attractiveness to payers, what does this really mean? this panel will deliver provocative views on attempts to formulate recipes to develop a go-to-market strategy.

FOcUs On OncOLOGY & PeRsOnALiZed Medicine

In this session, experienced dealmakers, pharma leaders and diagnostic development experts will explore: leveraging key factors of success for personalized approach to oncology drug development,

Predicting a changing regulatory environment and its impact on translating biomarkers to the clinic and into the marketplace,

Identifying the new players emerging within the personalized medicine space (i.e., emerging companies, re-modeled companies, institutes, patient-centered social media),

Understanding drivers for strategic decision making in oncology drug development.

11:00 - 11:30 networking break

11:30 - 13:00 tHeRAPeUtic insiGHt

Jean deReGnAUcOURt, Executive vice President Business Development, institut Pasteur (FR) denis MReJen, associate Director, Fsc Group (FR) Gilles nObecOURt, associate Director, edmond de Rotschild investment Partners (FR) bernard dAUGReAs, Chairman of the board, Auriga Partners (FR)

Herve LiLLiU, vice President global health outcomes, market access and Pricing, Ucb (B) Jan POstHUMUs, Head of global Market access and Market Research, basilea Pharmaceuticals (CH)

catherine beRens, Policy officer, european commission (BE)

christophe tHURieAU, vP scientific affairs, President Ipsen Innovation, ipsen Group (FR) Pr. bertrand cOiFFieR, european institute of Lymphoma, University of lyon, France (FR)

stephan cHALOn, Head of Research & translational Medicine Institute, Roche (CH) dominique bAGnARd, CEo, MtP therapeutics (FR)

the Universal Biotech Innovation Prize confers visibility to promising innovations and aims at facilitating partnership between the public and private stakeholders. It is a unique opportunity to identify promising and innovative projects.the Universal Biotech Innovation Prize is open to young innovative companies and to academic researchers on:

P R E l I m I N A R Y P R O G R A m T u E S D A Y , O C T O B E R 2 N D , 2 0 1 2

4:00 - 5:00 Presenting session: innovation Prize Finalists

5:00 - 5:30 innovation Prize ceremony

5:30 - 6:00 closing networking break

1:00 - 2:00 Lunch

FOcUs On centRAL neRVOUs sYsteM

Cns disorders represent a significant unmet medical need and societal burden and yet pose challenges for investment by the biotech and pharma Industry. solutions will be discussed from recent scientific discoveries and from novel partnership structures with biotech companies, academic investigators, advocacy organizations and governmental authorities.

2:00 - 3:30 tHeRAPeUtic insiGHt

 david s. Goldstein, senior Investigator and Chief, national institutes of Health (Usa)

timothy Herpin, vice-President strategic Partnering and Business Development, Cns and Pain, Astrazeneca (sW) Armin Giese, Center for neuropathology and Prion Research, Ludwig-Maximilian-University, Munich (DE)

3:30 - 4:00 networking break

Selection criteria: search for Excellence

Innovation degree

Industrial Property

Financing

Chances of success on the market

1st, 2nd & 3Rd OctObeR 2012Cité Internationale Universitaire of Paris, France

www.lifescience-outlook.com/innovationdays2012/homepage

universal medica Group342 Bureaux de la Colline92213 saint-Cloud+33 (1) 41 12 27 77

Rafi Mardachti, general Managerrafi.mardachti@universalmedica.com

aurélia Ringard, Business Developeraurelia.ringard@universalmedica.com

Find OUt MORe...

cOntActs